Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel + Pembrolizumab vs Pembrolizumab in Untreated Advanced Melanoma
NCT05727904Phase 3Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of lifileucel in melanoma (2 arms), sponsored by Iovance Biotherapeutics. Primary endpoints: Objective Response Rate at 5 years and Progression Free Survival at 5 years. Started Mar 2023; status: recruiting.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05727904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727904.